My name is Steve Johns and I am president of Confluence. We are developing a novel, first-in-class drug therapy for a rare orphan disease, Fragile X Syndrome and an adjoining disorder, Autism. These diseases represent a large unmet need market estimated at $25 Billion per year. Today, there are no approved medications that mitigate the core impairments for either disorder. We are raising $2 million in this round with $1.1 million already raised, have $520,000 in new verbal commitments, and we are seeking the remaining $380,000 in investment to complete two immediate value enhancing milestones and explore potential exit opportunities.
At Confluence, we recently received an inspiring story from the parents of a minimally verbal six-year-old boy with Fragile X Syndrome who experienced remarkable results after receiving our drug treatment in an investigator-led pilot study. They said that within days of starting the treatment, he began using words. The words kept flowing, his family called it "stored vocabulary ready to burst out." Treatment meant he could focus long enough to hear a complete bedtime story. This seems simple to parents with normal children, but it is profound for Fragile X and Autism patients and their parents who are on this journey. It demonstrates the kind of potential our therapeutic holds for our patients and the unprecedented value to investors.
Our lead therapeutic candidate has demonstrated the ability to rescue communications, social and cognitive deficits in multiple investigator-led clinical studies. Our medication will be a chronic care therapy and exploits a competitive therapeutic gap as the only one-drug solution in development that modulates receptors for both Glutamate and GABA, two dysregulated neurotransmitters impacting learning, language and social behavior. We are positioned to mirror our efficacy findings in a Phase 2/3 clinical trial. Confluence has supporting efficacy data, a defined regulatory path, Orphan Drug Designations, completed a successful Phase I regulatory clinical trial and has multiple patents providing defensible IP. Our product is commercial ready. Beyond Fragile X/Autism, we believe our treatment can benefit similarly anchored disorders like Rett Syndrome and Treatment-Resistant Anxiety. In addition to human applications, we have been approached to explore opportunities in animal health.
We would love to share more about our technology and how it could benefit your portfolio. I stand ready to schedule a introductory call to discuss our project.
Ready to Ask For Funding for your company?
Post a Funding Request